The Medicines Patent Pool invites MPP licensees to submit interest in a sublicence for dolutegravir (DTG)
2 décembre 2020
The Medicines Patent Pool (MPP) has just opened a call for expression of interest (EoI) inviting MPP licensees already manufacturing dolutegravir-approved products to take up a licence for dolutegravir (DTG) adults UMICs. DTG is recommended by the World Health Organization (WHO) as part of the preferred first-line and second-line regimen for people living with HIV, including pregnant women and those of childbearing potential.
This call follows on from the signing of a new voluntary licensing agreement between ViiV Healthcare and MPP in November 2020 to enable greater access of DTG-based regimens in certain upper-middle-income countries (UMICs). This new licensing agreement includes Azerbaijan, Belarus, Kazakhstan and Malaysia.
The agreement allows sublicensees to manufacture and supply DTG-based products to Azerbaijan, Belarus, Kazakhstan and Malaysia. Please note that applicants must already have a signed sublicence with MPP on DTG and have dolutegravir-approved products.
Submission deadline: 18 December 2020
For any questions regarding the EOI Portal or this application, please email firstname.lastname@example.org.
News & Communiqués de presse » Communiqués de presse
ViiV Healthcare et le Medicines Patent Pool concluent un nouvel accord de licence pour améliorer l’accès des personnes vivant avec le VIH aux médicaments à base de dolutégravir en Azerbaïdjan, au Bélarus, au Kazakhstan et en Malaisie
30 novembre 2020